Impact of COVID-19 on Drug Development in Rare Disease and Oncology

The full effect of the COVID-19 pandemic, particularly on the search for rare disease and oncology treatments, is still uncertain. What we do know is that patients diagnosed with these conditions simply cannot afford delays. With a patient-centric approach and guided by the best minds in the industry, Parexel has a broad perspective to help sponsors, regulators, and patients during this difficult time. We have learned a great deal over the past few months about trial conduct, patient recruitment, risk mitigation, the pace of regulatory approvals, and how patients are faring. And now we want to share this information with you.


Open PDF

Return to Insights Center

Related Insights

Blog

Parexel names first Patient Ambassador

Jun 17, 2022

Blog

Studying rare cancer patient populations using integrated genomic and real-world data

Aug 30, 2023

Blog

Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Article

Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Nov 10, 2022

Blog

Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development

Jun 22, 2021

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022

Article

Q&A Project Optimus: What you need to know

Oct 11, 2022

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Article

Three ways to work with the FDA for better patient-focused trials

Jul 29, 2021

Blog

Highlights from ASCO: Our experts weigh in

Jul 13, 2021

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023